21st.BIO

Virum, Denmark Founded: 2020 • Age: 6 yrs
Market research services for the biopharma sector are provided.
Request Access

About 21st.BIO

21st.BIO is a company based in Virum (Denmark) founded in 2020.. 21st.BIO has raised $152.85 million across 3 funding rounds from investors including Novo Holdings. The company has 38 employees as of November 30, 2024. 21st.BIO offers products and services including Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and Agriculture Solutions.

  • Headquarter Virum, Denmark
  • Employees 38 as on 30 Nov, 2024
  • Stage Minicorn
  • Sectors
    Consumer
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name 21St.Bio A/S
Operational Areas
Consumer → Food, Beverage & Nutrition
Key Metrics
  • Annual Revenue
  • Net Profit
    $-5.19 M (USD)
    -68
    as on Dec 31, 2022
  • EBITDA
    $-7.68 M (USD)
    -149
    as on Dec 31, 2022
  • Total Equity Funding
    $152.85 M (USD)

    in 3 rounds

  • Latest Funding Round
    $21.76 M (USD), Series C

    Jun 01, 2023

  • Investors
  • Employee Count
    38

    as on Nov 30, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of 21st.BIO

21st.BIO offers a comprehensive portfolio of products and services, including Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and Agriculture Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Development and scaling of proteins for dairy applications

Optimized sweeteners for food and industrial use

Production of collagen for biomaterials and health sectors

Advanced materials for various industrial applications

Strain development for agricultural biomining processes

Techniques for resource extraction in mining industries

People of 21st.BIO
Headcount 10-50
Employee Profiles 28
Employee Profiles
People
Thomas Kabel
CFO
People
Barbara Taudorf Andersen
Commercial Development and Strategic Partnerships
People
Karen Appel
Research Associate
People
Brittany Warr
Administrative Assistant

Unlock access to complete

Funding Insights of 21st.BIO

21st.BIO has successfully raised a total of $152.85M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $21.76 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $21.8M
  • First Round

    (17 Dec 2021)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2023 Amount Series C - 21st.BIO Valuation

investors

Sep, 2022 Amount Series C - 21st.BIO Valuation

investors

Dec, 2021 Amount Series C - 21st.BIO Valuation Novo Holdings
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in 21st.BIO

21st.BIO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Private equity and venture capital fund focused on the healthcare sector
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by 21st.BIO

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - 21st.BIO

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

21St.Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of 21st.BIO

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on 21St.Bio

Frequently Asked Questions about 21st.BIO

When was 21st.BIO founded?

21st.BIO was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is 21st.BIO located?

21st.BIO is headquartered in Virum, Denmark.

Is 21st.BIO a funded company?

21st.BIO is a funded company, having raised a total of $152.85M across 3 funding rounds to date. The company's 1st funding round was a Series C of $96.9M, raised on Dec 17, 2021.

How many employees does 21st.BIO have?

As of Nov 30, 2024, the latest employee count at 21st.BIO is 38.

What does 21st.BIO do?

21st.BIO was established in 2020 and is based in Virum, Denmark. Market research tailored to the biopharma industry is conducted, with a focus on data analysis and sector insights. Services encompass competitive intelligence, trend forecasting, and strategic advisory support. Operations are directed toward assisting pharmaceutical and biotechnology firms with evidence-based decision-making across global markets.

What products or services does 21st.BIO offer?

21st.BIO offers Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and 2 more products and services.

Who are 21st.BIO's investors?

21st.BIO has 1 investor. Key investors include Novo Holdings.

What is 21st.BIO's valuation?

The valuation of 21st.BIO is $91.79M as of Jun 2023.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available